Disposition of valproic acid in man
- PMID: 336377
- DOI: 10.1007/BF00645133
Disposition of valproic acid in man
Abstract
The pharmacokinetics of valproic acid (VPA) have been studied in 6 healthy subjects following a single 600 mg dose, and after multiple doses over 12 days (1200 mg daily) of enteric-coated sodium valproate. A time lag before absorption of 1 to 2 h was observed in each subject, and then absorption was rapid, peak concentrations being recorded 3 to 4 h after administration of the dose. The plasma level decline was biphasic with a terminal half-life of 15.9 +/- 2.6 h in the single dose and 17.3 +/- 3.0 h in the multiple dose experiments. There was no evidence of dose dependent kinetics or autoinduction. Total plasma clearance was 0.0064 +/- 0.0011 l/kg X h. The apparent volume of distribution was small at 0.15 +/- 0.2 l/kg. The mean steady state plasma concentration (Css) reached after 4 days was 81.3 +/- 13.0 microgram/ml. Css observed was lower than Css predicted (99.2 +/- 14.7 microgram/ml) from single dose kinetics (p less than 0.001). The difference was probably due to a reduction in plasma protein binding at higher concentrations. VPA concentration in saliva was between 0.4 and 4.5% of the total plasma concentration and was not equal to the concentration of unbound drug in plasma (6.7 +/- 0.8% unbound). 3.2% of the dose was excreted in urine as the parent drug and 21.2% as conjugated metabolites.
Similar articles
-
Prediction of steady-state concentrations of valproic acid as determined from single plasma concentrations after the first dose.Clin Pharm. 1983 Mar-Apr;2(2):143-7. Clin Pharm. 1983. PMID: 6411412
-
Pharmacokinetic studies with valproic acid in man.Arzneimittelforschung. 1977;27(5):1085-8. Arzneimittelforschung. 1977. PMID: 328019
-
Pharmacokinetics of valproic acid in volunteers after a single dose study.Biopharm Drug Dispos. 1985 Jan-Mar;6(1):33-42. doi: 10.1002/bdd.2510060105. Biopharm Drug Dispos. 1985. PMID: 3921078
-
Therapeutic monitoring of valproic acid.Ther Drug Monit. 1980;2(1):61-71. doi: 10.1097/00007691-198001000-00008. Ther Drug Monit. 1980. PMID: 6820201 Review.
-
Monitoring of free valproic acid levels?Ther Drug Monit. 1980;2(2):199-201. doi: 10.1097/00007691-198004000-00015. Ther Drug Monit. 1980. PMID: 6820203 Review. No abstract available.
Cited by
-
Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.Clin Pharmacokinet. 1996 Aug;31(2):120-30. doi: 10.2165/00003088-199631020-00004. Clin Pharmacokinet. 1996. PMID: 8853934 Review.
-
Clinical pharmacokinetics of valproic acid--1988.Clin Pharmacokinet. 1988 Dec;15(6):367-89. doi: 10.2165/00003088-198815060-00002. Clin Pharmacokinet. 1988. PMID: 3149565 Review.
-
A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations.PLoS Comput Biol. 2017 Feb 2;13(2):e1005280. doi: 10.1371/journal.pcbi.1005280. eCollection 2017 Feb. PLoS Comput Biol. 2017. PMID: 28151932 Free PMC article.
-
Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture.Exp Brain Res. 1990;81(2):313-7. doi: 10.1007/BF00228121. Exp Brain Res. 1990. PMID: 2168843
-
Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients.Br J Clin Pharmacol. 1982 Sep;14(3):399-404. doi: 10.1111/j.1365-2125.1982.tb01998.x. Br J Clin Pharmacol. 1982. PMID: 6812608 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources